VolitionRx Limited Reports Q4 2025 Earnings: Revenue Down 25%, Net Loss Widens

miércoles, 1 de abril de 2026, 1:44 pm ET1 min de lectura
VNRX--

VolitionRx Limited (VNRX) reported its Q4 2025 earnings, with CEO Cameron Reynolds and CFO Terig Hughes participating in the call. The company discussed its financial performance and future outlook, but the details of the call were not provided.

VolitionRx Limited Reports Q4 2025 Earnings: Revenue Down 25%, Net Loss Widens

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios